Lapatinib in early breast cancer?questions to be resolved
Mené sur 3 161 femmes atteintes d'un cancer du sein HER2+ de stade précoce, cet essai de phase III évalue un traitement adjuvant au lapatinib (12 mois), du point de vue de la survie sans maladie (durée médiane de suivi : 48 mois)
In 2005, the first results of the jointly analysed National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 and North Central Cancer Treatment Group (NCCTG) N9831 trials prompted use of trastuzumab for adjuvant treatment of HER2-positive breast cancer worldwide. The same year, the first results of a trial of lapatinib monotherapy in metastatic cancer was reported, and, in 2006, Charles E Geyer and colleagues reported findings from a randomised study of the use of lapatinib to improve therapeutic efficacy of capecitabine in patients with advanced breast cancer previously treated with trastuzumab...
The Lancet Oncology , commentaire en libre accès, 2011